Managing Multiorgan Failure in Acute on Chronic Liver Failure

Abstract

Acute-on-chronic liver failure (ACLF) is defined as a clinical syndrome that develops in patients with chronic liver disease characterized by the presence of organ failure and high short-term mortality, although there is still no worldwide consensus on diagnostic criteria. Management of ACLF is mainly based on treatment of “precipitating factors” (the most common are infections, alcohol-associated hepatitis, hepatitis B flare, and bleeding) and support of organ failure, which often requires admission to the intensive care unit. Liver transplantation should be considered in patients with ACLF grades 2 to 3 as a potentially life-saving treatment. When a transplant is not indicated, palliative care should be considered after 3 to 7 days of full organ support in patients with at least four organ failures or a CLIF-C ACLF score of >70. This review summarizes the current knowledge on the management of organ failure in patients with ACLF, focusing on recent advances.

Keywords

ACLF - acute decompensation - cirrhosis - hepatology - liver transplantation

Ethical Approval Statement

Not applicable.

Publication History

Accepted Manuscript online:
23 October 2024

Article published online:
14 November 2024

• References

• 1 Arroyo V, Moreau R, Jalan R. Acute-on-chronic liver failure. N Engl J Med 2020; 382 (22) 2137-2145
• 2 Bajaj JS, O'Leary JG, Reddy KR. et al; North American Consortium for the Study of End-Stage Liver Disease (NACSELD). Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology 2014; 60 (01) 250-256
• 3 Moreau R, Jalan R, Gines P. et al; CANONIC Study Investigators of the EASL–CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144 (07) 1426-1437 , 1437.e1–1437.e9
• 4 Sarin SK, Choudhury A, Sharma MK. et al; APASL ACLF Research Consortium (AARC) for APASL ACLF working Party.. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL): an update. Hepatol Int 2019; 13 (04) 353-390
• 5 Kulkarni AV, Sarin SK. Acute-on-chronic liver failure - steps towards harmonization of the definition!. J Hepatol 2024; 81 (02) 360-366
• 6 Bajaj JS, O'Leary JG, Lai JC. et al. Acute-on-chronic liver failure clinical guidelines. Am J Gastroenterol 2022; 117 (02) 225-252
• 7 Moreau R, Tonon M, Krag A. et al; European Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver. EASL Clinical Practice Guidelines on acute-on-chronic liver failure. J Hepatol 2023; 79 (02) 461-491
• 8 Karvellas CJ, Bajaj JS, Kamath PS. et al. AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis. Hepatology 2024; 79 (06) 1463-1502
• 9 Meersseman P, Langouche L, du Plessis J. et al. The intensive care unit course and outcome in acute-on-chronic liver failure are comparable to other populations. J Hepatol 2018; 69 (04) 803-809
• 10 Artru F, Louvet A, Ruiz I. et al. Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3. J Hepatol 2017; 67 (04) 708-715
• 11 Gustot T, Fernandez J, Garcia E. et al; CANONIC Study Investigators of the EASL-CLIF Consortium. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 2015; 62 (01) 243-252
• 12 Trebicka J, Fernandez J, Papp M. et al; PREDICT Study Group of the EASL-CLIF CONSORTIUM. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. J Hepatol 2021; 74 (05) 1097-1108
• 13 Wu T, Li J, Shao L. et al; Chinese Group on the Study of Severe Hepatitis B (COSSH).. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut 2018; 67 (12) 2181-2191
• 14 Arroyo V, Angeli P, Moreau R. et al; investigators from the EASL-CLIF Consortium, Grifols Chair and European Foundation for the Study of Chronic Liver Failure (EF-Clif). The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol 2021; 74 (03) 670-685
• 15 Wong F, Piano S, Singh V. et al; International Club of Ascites Global Study Group. Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. J Hepatol 2021; 74 (02) 330-339
• 16 Fernández J, Acevedo J, Wiest R. et al; European Foundation for the Study of Chronic Liver Failure. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut 2018; 67 (10) 1870-1880
• 17 Piano S, Singh V, Caraceni P. et al; International Club of Ascites Global Study Group. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology 2019; 156 (05) 1368-1380.e10
• 18 Fernández J, Piano S, Bartoletti M, Wey EQ. Management of bacterial and fungal infections in cirrhosis: The MDRO challenge. J Hepatol 2021; 75 (Suppl. 01) S101-S117
• 19 Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F. et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. Aliment Pharmacol Ther 2011; 34 (05) 509-518
• 20 Bartoletti M, Giannella M, Caraceni P. et al. Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. J Hepatol 2014; 61 (01) 51-58
• 21 Thursz MR, Richardson P, Allison M. et al; STOPAH Trial. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015; 372 (17) 1619-1628
• 22 Sersté T, Cornillie A, Njimi H. et al. The prognostic value of acute-on-chronic liver failure during the course of severe alcoholic hepatitis. J Hepatol 2018; 69 (02) 318-324
• 23 Forrest EH, Atkinson SR, Richardson P. et al; STOPAH Trial Management Group. Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis. J Hepatol 2018; 69 (05) 1200-1201
• 24 Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011; 53 (03) 774-780
• 25 de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Baveno VII Faculty. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022; 76 (04) 959-974
• 26 Villanueva C, Colomo A, Bosch A. et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368 (01) 11-21
• 27 Trebicka J, Gu W, Ibáñez-Samaniego L. et al; International Variceal Bleeding Observational Study Group and Baveno Cooperation. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. J Hepatol 2020; 73 (05) 1082-1091
• 28 Shi Y, Yang Y, Hu Y. et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology 2015; 62 (01) 232-242
• 29 Juanola A, Tiwari N, Solé C, Adebayo D, Wong F, Ginès P. Organ dysfunction and failure in liver disease. Liver Int 2023
• 30 Ariza X, Graupera I, Coll M. et al; CANONIC Investigators, EASL CLIF Consortium. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. J Hepatol 2016; 65 (01) 57-65
• 31 Juanola A, Graupera I, Elia C. et al. Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis. J Hepatol 2022; 76 (01) 107-114
• 32 Grønbæk H, Rødgaard-Hansen S, Aagaard NK. et al; CANONIC study investigators of the EASL-CLIF Consortium. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). J Hepatol 2016; 64 (04) 813-822
• 33 Kerbert AJC, Gupta S, Alabsawy E. et al. Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure. JHEP Rep Innov Hepatol 2021; 3 (06) 100355
• 34 Ballester MP, Elshabrawi A, Jalan R. Extracorporeal liver support and liver transplantation for acute-on-chronic liver failure. Liver Int 2023
• 35 Adejumo A, Noll A, Rogal SS. et al. Dementia frequently coexists with hepatic encephalopathy but not other cirrhosis complications in US Veterans. Am J Gastroenterol 2023; 118 (03) 475-480
• 36 Montagnese S, Rautou PE, Romero-Gómez M. et al; European Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol 2022; 77 (03) 807-824
• 37 Shalimar, Sheikh MF, Mookerjee RP, Agarwal B, Acharya SK, Jalan R. Prognostic role of ammonia in patients with cirrhosis. Hepatology 2019; 70 (03) 982-994
• 38 Verma N, Dhiman RK, Choudhury A. et al; APASL ACLF Research Consortium (AARC) for APASL ACLF working Party. Dynamic assessments of hepatic encephalopathy and ammonia levels predict mortality in acute-on-chronic liver failure. Hepatol Int 2021; 15 (04) 970-982
• 39 Li M, Zhang Z, Chen Q, Zhou X, Shui D, Huang J. Comparative effectiveness and safety of polyethylene glycol electrolyte solution versus lactulose for treatment of hepatic encephalopathy: a systematic review and meta-analysis. J Clin Gastroenterol 2022; 56 (01) 41-48
• 40 Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013; 108 (09) 1458-1463
• 41 Simón-Talero M, García-Martínez R, Torrens M. et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol 2013; 59 (06) 1184-1192
• 42 Joshi D, O'Grady J, Patel A. et al. Cerebral oedema is rare in acute-on-chronic liver failure patients presenting with high-grade hepatic encephalopathy. Liver Int 2014; 34 (03) 362-366
• 43 Rabinstein AA. Treatment of brain edema in acute liver failure. Curr Treat Options Neurol 2010; 12 (02) 129-141
• 44 Bañares R, Nevens F, Larsen FS. et al; RELIEF Study Group. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 2013; 57 (03) 1153-1162
• 45 Cardoso FS, Gottfried M, Tujios S, Olson JC, Karvellas CJ. US Acute Liver Failure Study Group. Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure. Hepatology 2018; 67 (02) 711-720
• 46 Piano S, Tonon M, Vettore E. et al. Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis. J Hepatol 2017; 67 (06) 1177-1184
• 47 Wong F, Reddy KR, Tandon P. et al. The prediction of in-hospital mortality in decompensated cirrhosis with acute-on-chronic liver failure. Liver Transpl 2022; 28 (04) 560-570
• 48 Maiwall R, Singh SP, Angeli P. et al. APASL clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure. Hepatol Int 2024; 18 (03) 833-869
• 49 Angeli P, Ginès P, Wong F. et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015; 62 (04) 968-974
• 50 Yoo JJ, Kim SG, Kim YS. et al. Estimation of renal function in patients with liver cirrhosis: impact of muscle mass and sex. J Hepatol 2019; 70 (05) 847-854
• 51 Di Cola S, D'Amico G, Caraceni P. et al; EpatoSarco Working Group. Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis. J Hepatol 2024; 81 (04) 641-650
• 52 Nadim MK, Kellum JA, Forni L. et al. Acute kidney injury in patients with cirrhosis: acute disease quality initiative (ADQI) and international club of ascites (ICA) joint multidisciplinary consensus meeting. J Hepatol 2024; 81 (01) 163-183
• 53 Singapura P, Ma TW, Sarmast N. et al. Estimating glomerular filtration rate in cirrhosis using creatinine-based and cystatin C-based equations: systematic review and meta-analysis. Liver Transpl 2021; 27 (11) 1538-1552
• 54 Fickert P, Rosenkranz AR. Cholemic nephropathy reloaded. Semin Liver Dis 2020; 40 (01) 91-100
• 55 Pose E, Piano S, Juanola A, Ginès P. Hepatorenal syndrome in cirrhosis. Gastroenterology 2024; 166 (04) 588-604.e1
• 56 Maiwall R, Kumar S, Chandel SS. et al. AKI in patients with acute on chronic liver failure is different from acute decompensation of cirrhosis. Hepatol Int 2015; 9 (04) 627-639
• 57 Huelin P, Solà E, Elia C. et al. Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: a prospective study. Hepatology 2019; 70 (01) 319-333
• 58 Allegretti AS, Parada XV, Endres P. et al; HRS-HARMONY Study Investigators. Urinary NGAL as a diagnostic and prognostic marker for acute kidney injury in cirrhosis: a prospective study. Clin Transl Gastroenterol 2021; 12 (05) e00359
• 59 Ma AT, Solé C, Juanola A. et al. Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis. J Hepatol 2024; 81 (03) 441-450
• 60 Lichtenstein DA. Lung ultrasound in the critically ill. Ann Intensive Care 2014; 4 (01) 1
• 61 Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56 (09) 1310-1318
• 62 Sanyal AJ, Boyer T, Garcia-Tsao G. et al; Terlipressin Study Group. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134 (05) 1360-1368
• 63 Martín-Llahí M, Pépin MN, Guevara M. et al; TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134 (05) 1352-1359
• 64 Boyer TD, Sanyal AJ, Wong F. et al; REVERSE Study Investigators. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology 2016; 150 (07) 1579-1589.e2
• 65 Wong F, Pappas SC, Curry MP. et al; CONFIRM Study Investigators. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med 2021; 384 (09) 818-828
• 66 Ding C, Wu X, Fan X, He C, Li J. Hemodynamic effects of continuous versus bolus infusion of terlipressin for portal hypertension: a randomized comparison. J Gastroenterol Hepatol 2013; 28 (07) 1242-1246
• 67 Cavallin M, Piano S, Romano A. et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology 2016; 63 (03) 983-992
• 68 Piano S, Schmidt HH, Ariza X. et al; EASL CLIF Consortium, European Foundation for the Study of Chronic Liver Failure (EF Clif). Association between grade of acute on chronic liver failure and response to terlipressin and albumin in patients with hepatorenal syndrome. Clin Gastroenterol Hepatol 2018; 16 (11) 1792-1800.e3
• 69 Wong F, Pappas SC, Reddy KR. et al. Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure. Aliment Pharmacol Ther 2022; 56 (08) 1284-1293
• 70 Alessandria C, Ottobrelli A, Debernardi-Venon W. et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007; 47 (04) 499-505
• 71 Singh V, Ghosh S, Singh B. et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 2012; 56 (06) 1293-1298
• 72 Arora V, Maiwall R, Rajan V. et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology 2020; 71 (02) 600-610
• 73 Allegretti AS, Parada XV, Eneanya ND. et al. Prognosis of patients with cirrhosis and AKI who initiate RRT. Clin J Am Soc Nephrol 2018; 13 (01) 16-25
• 74 Ostermann M, Joannidis M, Pani A. et al; 17th Acute Disease Quality Initiative (ADQI) Consensus Group. Patient selection and timing of continuous renal replacement therapy. Blood Purif 2016; 42 (03) 224-237
• 75 Engelmann C, Clària J, Szabo G, Bosch J, Bernardi M. Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol 2021; 75 (Suppl. 01) S49-S66
• 76 Liu H, Naser JA, Lin G, Lee SS. Cardiomyopathy in cirrhosis: from pathophysiology to clinical care. JHEP Rep Innov Hepatol 2024; 6 (01) 100911
• 77 Angeli P, Bernardi M, Villanueva C. et al; European Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69 (02) 406-460
• 78 Cardoso FS, Pereira R, Laranjo A. et al. Positive fluid balance was associated with mortality in patients with acute-on-chronic liver failure: a cohort study. J Crit Care 2021; 63: 238-242
• 79 Finfer S, Micallef S, Hammond N. et al; PLUS Study Investigators and the Australian New Zealand Intensive Care Society Clinical Trials Group. Balanced multielectrolyte solution versus saline in critically ill adults. N Engl J Med 2022; 386 (09) 815-826
• 80 Pompili E, Zaccherini G, Baldassarre M, Iannone G, Caraceni P. Albumin administration in internal medicine: a journey between effectiveness and futility. Eur J Intern Med 2023; 117: 28-37
• 81 Philips CA, Maiwall R, Sharma MK. et al. Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial. Hepatol Int 2021; 15 (04) 983-994
• 82 Maiwall R, Kumar A, Pasupuleti SSR. et al. A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]. J Hepatol 2022; 77 (03) 670-682
• 83 Maiwall R, Rao Pasupuleti SS, Hidam AK. et al. A randomised-controlled trial (TARGET-C) of high vs. low target mean arterial pressure in patients with cirrhosis and septic shock. J Hepatol 2023; 79 (02) 349-361
• 84 Schulz MS, Mengers J, Gu W. et al. Pulmonary impairment independently determines mortality in critically ill patients with acute-on-chronic liver failure. Liver Int 2023; 43 (01) 180-193
• 85 Levesque E, Saliba F, Ichaï P, Samuel D. Outcome of patients with cirrhosis requiring mechanical ventilation in ICU. J Hepatol 2014; 60 (03) 570-578
• 86 Biggins SW, Angeli P, Garcia-Tsao G. et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 74 (02) 1014-1048
• 87 Ni YN, Luo J, Yu H. et al. Can high-flow nasal cannula reduce the rate of endotracheal intubation in adult patients with acute respiratory failure compared with conventional oxygen therapy and noninvasive positive pressure ventilation?: A systematic review and meta-analysis. Chest 2017; 151 (04) 764-775
• 88 Frat JP, Coudroy R, Marjanovic N, Thille AW. High-flow nasal oxygen therapy and noninvasive ventilation in the management of acute hypoxemic respiratory failure. Ann Transl Med 2017; 5 (14) 297
• 89 Carrillo A, Lopez A, Carrillo L. et al. Validity of a clinical scale in predicting the failure of non-invasive ventilation in hypoxemic patients. J Crit Care 2020; 60: 152-158
• 90 Petrucci N, De Feo C. Lung protective ventilation strategy for the acute respiratory distress syndrome. Cochrane Database Syst Rev 2013; 2013 (02) CD003844
• 91 Walkey AJ, Del Sorbo L, Hodgson CL. et al. Higher PEEP versus lower PEEP strategies for patients with acute respiratory distress syndrome. a systematic review and meta-analysis. Ann Am Thorac Soc 2017; 14 (Suppl. 04) S297-S303
• 92 Simonis FD, Serpa Neto A, Binnekade JM. et al; Writing Group for the PReVENT Investigators. Effect of a low vs intermediate tidal volume strategy on ventilator-free days in intensive care unit patients without ARDS: a randomized clinical trial. JAMA 2018; 320 (18) 1872-1880
• 93 Chou AH, Wu VCC, Chen DY. et al. Outcome of extracorporeal membrane oxygenation support in patients with liver cirrhosis: a nationwide population-based cohort study. Eur J Cardiothorac Surg 2020; 58 (03) 519-527
• 94 Krowka MJ, Fallon MB, Kawut SM. et al. International liver transplant society practice guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension. Transplantation 2016; 100 (07) 1440-1452
• 95 Thuluvath PJ, Thuluvath AJ, Hanish S, Savva Y. Liver transplantation in patients with multiple organ failures: feasibility and outcomes. J Hepatol 2018; 69 (05) 1047-1056
• 96 Sundaram V, Jalan R, Wu T. et al. Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation. Gastroenterology 2019; 156 (05) 1381-1391.e3
• 97 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365 (02) 147-156
• 98 Zanetto A, Northup P, Roberts L, Senzolo M. Haemostasis in cirrhosis: understanding destabilising factors during acute decompensation. J Hepatol 2023; 78 (05) 1037-1047
• 99 Premkumar M, Saxena P, Rangegowda D. et al. Coagulation failure is associated with bleeding events and clinical outcome during systemic inflammatory response and sepsis in acute-on-chronic liver failure: an observational cohort study. Liver Int 2019; 39 (04) 694-704
• 100 Villa E, Bianchini M, Blasi A. et al; European Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol 2022; 76 (05) 1151-1184
• 101 Rout G, Shalimar, Gunjan D. et al. Thromboelastography-guided blood product transfusion in cirrhosis patients with variceal bleeding: a randomized controlled trial. J Clin Gastroenterol 2020; 54 (03) 255-262
• 102 Kumar M, Ahmad J, Maiwall R. et al. Thromboelastography-guided blood component use in patients with cirrhosis with nonvariceal bleeding: a randomized controlled trial. Hepatology 2020; 71 (01) 235-246
• 103 De Pietri L, Bianchini M, Montalti R. et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: a randomized, controlled trial. Hepatology 2016; 63 (02) 566-573
• 104 Riescher-Tuczkiewicz A, Caldwell SH, Kamath PS, Villa E, Rautou PE. Bleeding in Liver Diseases Investigators†, Bleeding in Liver Diseases Investigators. Expert opinion on bleeding risk from invasive procedures in cirrhosis. JHEP Rep Innov Hepatol 2023; 6 (03) 100986
• 105 O'Leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA Clinical Practice Update: coagulation in cirrhosis. Gastroenterology 2019; 157 (01) 34-43.e1
• 106 Villanueva C, Albillos A, Genescà J. et al. β Blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2019; 393 (10181): 1597-1608
• 107 Caraceni P, Riggio O, Angeli P. et al; ANSWER Study Investigators. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet 2018; 391 (10138): 2417-2429
• 108 Pompili E, Zaccherini G, Piano S. et al. Real-world experience with long-term albumin in patients with cirrhosis and ascites. JHEP Rep Innov Hepatol 2024 In press
• 109 Pose E, Jiménez C, Zaccherini G. et al. Simvastatin plus rifaximin to prevent ACLF in patients with decompensated cirrhosis. A randomised, double-blind, placebo-controlled, phase-3 trial: the liverhope efficacy trial. J Hepatol 2023; 78 (Suppl. 01) S10-S511
• 110 Trebicka J, Fernandez J, Papp M. et al; PREDICT STUDY Group of the EASL-CLIF Consortium. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol 2020; 73 (04) 842-854
• 111 Pompili E, Baldassarre M, Bedogni G. et al. Predictors of clinical trajectories of patients with acutely decompensated cirrhosis. An external validation of the PREDICT study. Liver Int 2024; 44 (01) 72-82
• 112 Juanola A, Ma AT, de Wit K. et al; LiverHope Investigators. Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis. Gut 2023; 73 (01) 156-165
• 113 Kim JJ, Tsukamoto MM, Mathur AK. et al. Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis. Am J Gastroenterol 2014; 109 (09) 1436-1442
• 114 NCEPOD - Alcohol Related Liver Disease: Measuring the Units. Published online 2013. Accessed November 3, 2024. Available at: https://www.ncepod.org.uk/2013arld.html
• 115 McPherson S, Dyson J, Austin A, Hudson M. Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosis-the first 24 h. Frontline Gastroenterol 2016; 7 (01) 16-23
• 116 Dyson JK, Rajasekhar P, Wetten A. et al. Implementation of a ‘care bundle’ improves the management of patients admitted to hospital with decompensated cirrhosis. Aliment Pharmacol Ther 2016; 44 (10) 1030-1038
• 117 Trainee Collaborative for Research and Audit in Hepatology UK. Admission care bundles for decompensated cirrhosis are poorly utilised across the UK: results from a multi-centre retrospective study. Clin Med (Lond) 2023; 23 (03) 193-200
• 118 Tandon P, Montano-Loza AJ, Lai JC, Dasarathy S, Merli M. Sarcopenia and frailty in decompensated cirrhosis. J Hepatol 2021; 75 (Suppl. 01) S147-S162
• 119 Moreno C, Deltenre P, Senterre C. et al. Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids. Gastroenterology 2016; 150 (04) 903-10.e8
• 120 Borhofen SM, Gerner C, Lehmann J. et al. The royal free hospital-nutritional prioritizing tool is an independent predictor of deterioration of liver function and survival in cirrhosis. Dig Dis Sci 2016; 61 (06) 1735-1743
• 121 Lai JC, Covinsky KE, McCulloch CE, Feng S. The liver frailty index improves mortality prediction of the subjective clinician assessment in patients with cirrhosis. Am J Gastroenterol 2018; 113 (02) 235-242
• 122 McClave SA, Taylor BE, Martindale RG. et al; Society of Critical Care Medicine, American Society for Parenteral and Enteral Nutrition. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2016; 40 (02) 159-211
• 123 Kribben A, Gerken G, Haag S. et al; HELIOS Study Group. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012; 142 (04) 782-789.e3
• 124 Karvellas CJ, Gustot T, Fernandez J. Management of the acute on chronic liver failure in the intensive care unit. Liver Int 2023
• 125 Bañares R, Ibáñez-Samaniego L, Torner JM. et al. Meta-analysis of individual patient data of albumin dialysis in acute-on-chronic liver failure: focus on treatment intensity. Therap Adv Gastroenterol 2019; 12: 17 56284819879565
• 126 Gerth HU, Pohlen M, Thölking G. et al. Molecular adsorbent recirculating system can reduce short-term mortality among patients with acute-on-chronic liver failure - a retrospective analysis. Crit Care Med 2017; 45 (10) 1616-1624
• 127 Agarwal B, Cañizares RB, Saliba F. et al. Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on-chronic liver failure. J Hepatol 2023; 79 (01) 79-92
• 128 Alcaraz-Quiles J, Casulleras M, Oettl K. et al. Oxidized albumin triggers a cytokine storm in leukocytes through p38 MAP kinase: role in systemic inflammation in decompensated cirrhosis. Hepatology 2018; 68 (05) 1937-1952
• 129 Fernández J, Lozano M, Torres M. et al. Effect of plasma exchange with albumin replacement on albumin functionality and organ dysfunction in acute-on-chronic liver failure. JHEP Rep Innov Hepatol 2024; 6 (04) 101017
• 130 Beran A, Mohamed MFH, Shaear M. et al. Plasma exchange for acute and acute-on-chronic liver failure: a systematic review and meta-analysis. Liver Transpl 2024; 30 (02) 127-141
• 131 Sundaram V, Lindenmeyer CC, Shetty K. et al; Multi-Organ Dysfunction and Evaluation for Liver Transplantation (MODEL) Consortium. Patients with acute-on-chronic liver failure have greater healthcare resource utilization after liver transplantation. Clin Gastroenterol Hepatol 2023; 21 (03) 704-712.e3
• 132 Hernaez R, Karvellas CJ, Liu Y. et al; Multi-Organ Dysfunction and Evaluation for Liver Transplantation (MODEL) Consortium. The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure. J Hepatol 2023; 79 (03) 717-727
• 133 Sundaram V, Patel S, Shetty K. et al; Multi-Organ Dysfunction and Evaluation for Liver Transplantation (MODEL) Consortium. Risk factors for posttransplantation mortality in recipients with grade 3 acute-on-chronic liver failure: analysis of a North American Consortium. Liver Transpl 2022; 28 (06) 1078-1089
• 134 Artzner T, Michard B, Weiss E. et al. Liver transplantation for critically ill cirrhotic patients: stratifying utility based on pretransplant factors. Am J Transplant 2020; 20 (09) 2437-2448
• 135 Artru F, Trovato F, Morrison M, Bernal W, McPhail M. Liver transplantation for acute-on-chronic liver failure. Lancet Gastroenterol Hepatol 2024; 9 (06) 564-576
• 136 Sundaram V, Kogachi S, Wong RJ. et al. Effect of the clinical course of acute-on-chronic liver failure prior to liver transplantation on post-transplant survival. J Hepatol 2020; 72 (03) 481-488
• 137 Singal AK, Kuo YF, Waleed M, Wong RJ, Sundaram V, Jalan R. High-risk liver transplant recipients with grade 3 acute on chronic liver failure should receive the good quality graft. Liver Int 2022; 42 (07) 1629-1637
• 138 Sundaram V, Shah P, Wong RJ. et al. Patients with acute on chronic liver failure grade 3 have greater 14-day waitlist mortality than status-1a patients. Hepatology 2019; 70 (01) 334-345
• 139 Hernaez R, Liu Y, Kramer JR, Rana A, El-Serag HB, Kanwal F. Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. J Hepatol 2020; 73 (06) 1425-1433
• 140 Artru F, Goldberg D, Kamath PS. Should patients with acute-on-chronic liver failure grade 3 receive higher priority for liver transplantation?. J Hepatol 2023; 78 (06) 1118-1123
• 141 Jalan R, Gines P, Olson JC. et al. Acute-on chronic liver failure. J Hepatol 2012; 57 (06) 1336-1348